284 related articles for article (PubMed ID: 19769736)
1. Witch hunt against tumor cells enhanced by dendritic cells.
Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
[TBL] [Abstract][Full Text] [Related]
2. Molecular characteristics of immunogenic cancer cell death.
Tesniere A; Panaretakis T; Kepp O; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
Cell Death Differ; 2008 Jan; 15(1):3-12. PubMed ID: 18007663
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic cancer cell death: a key-lock paradigm.
Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
[TBL] [Abstract][Full Text] [Related]
4. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
[TBL] [Abstract][Full Text] [Related]
5. Ecto-calreticulin in immunogenic chemotherapy.
Obeid M; Tesniere A; Panaretakis T; Tufi R; Joza N; van Endert P; Ghiringhelli F; Apetoh L; Chaput N; Flament C; Ullrich E; de Botton S; Zitvogel L; Kroemer G
Immunol Rev; 2007 Dec; 220():22-34. PubMed ID: 17979837
[TBL] [Abstract][Full Text] [Related]
6. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity.
Brusa D; Garetto S; Chiorino G; Scatolini M; Migliore E; Camussi G; Matera L
Vaccine; 2008 Nov; 26(50):6422-32. PubMed ID: 18848858
[TBL] [Abstract][Full Text] [Related]
7. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
[TBL] [Abstract][Full Text] [Related]
8. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
[TBL] [Abstract][Full Text] [Related]
9. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
10. [Immunological aspects of anticancer chemotherapy].
Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
[TBL] [Abstract][Full Text] [Related]
11. The immunogenicity of tumor cell death.
Kepp O; Tesniere A; Zitvogel L; Kroemer G
Curr Opin Oncol; 2009 Jan; 21(1):71-6. PubMed ID: 19125021
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic cell death modalities and their impact on cancer treatment.
Kepp O; Tesniere A; Schlemmer F; Michaud M; Senovilla L; Zitvogel L; Kroemer G
Apoptosis; 2009 Apr; 14(4):364-75. PubMed ID: 19145485
[TBL] [Abstract][Full Text] [Related]
13. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.
Michaud M; Martins I; Sukkurwala AQ; Adjemian S; Ma Y; Pellegatti P; Shen S; Kepp O; Scoazec M; Mignot G; Rello-Varona S; Tailler M; Menger L; Vacchelli E; Galluzzi L; Ghiringhelli F; di Virgilio F; Zitvogel L; Kroemer G
Science; 2011 Dec; 334(6062):1573-7. PubMed ID: 22174255
[TBL] [Abstract][Full Text] [Related]
14. HMGB1: a two-headed signal regulating tumor progression and immunity.
Campana L; Bosurgi L; Rovere-Querini P
Curr Opin Immunol; 2008 Oct; 20(5):518-23. PubMed ID: 18599281
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Obeid M; Ortiz C; Criollo A; Mignot G; Maiuri MC; Ullrich E; Saulnier P; Yang H; Amigorena S; Ryffel B; Barrat FJ; Saftig P; Levi F; Lidereau R; Nogues C; Mira JP; Chompret A; Joulin V; Clavel-Chapelon F; Bourhis J; André F; Delaloge S; Tursz T; Kroemer G; Zitvogel L
Nat Med; 2007 Sep; 13(9):1050-9. PubMed ID: 17704786
[TBL] [Abstract][Full Text] [Related]
16. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.
Apetoh L; Tesniere A; Ghiringhelli F; Kroemer G; Zitvogel L
Cancer Res; 2008 Jun; 68(11):4026-30. PubMed ID: 18519658
[TBL] [Abstract][Full Text] [Related]
17. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy.
Kepp O; Galluzzi L; Martins I; Schlemmer F; Adjemian S; Michaud M; Sukkurwala AQ; Menger L; Zitvogel L; Kroemer G
Cancer Metastasis Rev; 2011 Mar; 30(1):61-9. PubMed ID: 21249425
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic anti-cancer chemotherapy as an emerging concept.
Haynes NM; van der Most RG; Lake RA; Smyth MJ
Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
[TBL] [Abstract][Full Text] [Related]
19. Targeting to static endosome is required for efficient cross-presentation of endoplasmic reticulum-resident oxygen-regulated protein 150-peptide complexes.
Kutomi G; Tamura Y; Okuya K; Yamamoto T; Hirohashi Y; Kamiguchi K; Oura J; Saito K; Torigoe T; Ogawa S; Hirata K; Sato N
J Immunol; 2009 Nov; 183(9):5861-9. PubMed ID: 19812200
[TBL] [Abstract][Full Text] [Related]
20. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
Radfar S; Wang Y; Khong HT
J Immunol; 2009 Nov; 183(10):6800-7. PubMed ID: 19846868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]